Novartis's Blood-Disorder Drug Trial Meets Primary Endpoint
26 Abril 2023 - 7:15AM
Dow Jones News
By Cecilia Butini
Novartis AG said Wednesday that a Phase-3 trial to investigate a
drug to treat blood disorder paroxysmal nocturnal hemoglobinuria
has met its primary endpoint.
The drug, named iptacopan, is shown to improve hemoglobin levels
without the need for red blood cell transfusions, the company said.
Further, secondary trial endpoints were also met, it added.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
April 26, 2023 06:00 ET (10:00 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
